Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

doi:10.12688/f1000research.16517.2

Review

. 2019 Jan 30:8:F1000 Faculty Rev-121.

doi: 10.12688/f1000research.16517.2. eCollection 2019.

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Richard R Watkins^{1

2}, David Van Duin³

Affiliations

¹ Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA.
² Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA.
³ Department of Medicine, University of North Carolina, Chapel Hill, NC, 27514, USA.

PMID: 30755795
PMCID: PMC6354321
DOI: 10.12688/f1000research.16517.2

Review

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Richard R Watkins et al. F1000Res. 2019.

. 2019 Jan 30:8:F1000 Faculty Rev-121.

doi: 10.12688/f1000research.16517.2. eCollection 2019.

Authors

Richard R Watkins^{1

2}, David Van Duin³

Affiliations

¹ Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, 44302, USA.
² Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, 44272, USA.
³ Department of Medicine, University of North Carolina, Chapel Hill, NC, 27514, USA.

PMID: 30755795
PMCID: PMC6354321
DOI: 10.12688/f1000research.16517.2

Abstract

Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.

Keywords: Acinetobacter baumannii; Enterobacteriaceae; Pseudomonas aeruginosa; antibiotics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RRW serves on an advisory board and speakers’ bureau and has received research support from Allergan. DvD serves on advisory boards for Allergan, Achaogen, Shionogi, Tetraphase, Sanofi Pasteur, MedImmune, and Astellas and has received research funding from Steris Inc. and Scynexis.

Cited by

Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study.
Yang KY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, Chen CM, Chen CY, Zheng ZR, Feng JY; T-CARE (Taiwan Critical Care and Infection) Group. Yang KY, et al. J Intensive Care. 2023 Jan 3;11(1):1. doi: 10.1186/s40560-022-00647-y. J Intensive Care. 2023. PMID: 36597165 Free PMC article.
Determination of Antibiotic Resistance Genes in the Interior Bay of Puno-Peru, Lake Titicaca.
Ferro P, Rossel J, Ferro-Gonzales AL, Morales-Rojas E, Ticona E, Guevara R, Córdova L. Ferro P, et al. Scientifica (Cairo). 2025 Mar 21;2025:5571355. doi: 10.1155/sci5/5571355. eCollection 2025. Scientifica (Cairo). 2025. PMID: 40160312 Free PMC article.
Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study.
Feng JY, Huang JR, Lee CC, Tseng YH, Pan SW, Chen YM, Yang KY. Feng JY, et al. Ann Intensive Care. 2023 Jan 7;13(1):1. doi: 10.1186/s13613-022-01088-4. Ann Intensive Care. 2023. PMID: 36609725 Free PMC article.
Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns.
Assefa M. Assefa M. Pneumonia (Nathan). 2022 May 5;14(1):4. doi: 10.1186/s41479-022-00096-z. Pneumonia (Nathan). 2022. PMID: 35509063 Free PMC article. Review.
Salvadora persica mediated synthesis of silver nanoparticles and their antimicrobial efficacy.
Arshad H, Sami MA, Sadaf S, Hassan U. Arshad H, et al. Sci Rep. 2021 Mar 16;11(1):5996. doi: 10.1038/s41598-021-85584-w. Sci Rep. 2021. PMID: 33727607 Free PMC article.

See all "Cited by" articles

References

1. Thorpe KE, Joski P, Johnston KJ: Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Aff (Millwood). 2018;37(4):662–9. 10.1377/hlthaff.2017.1153 - DOI - PubMed
2. F1000 Recommendation
1. Kalil AC, Metersky ML, Klompas M, et al. : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. 10.1093/cid/ciw353 - DOI - PMC - PubMed
2. F1000 Recommendation
1. Bassetti M, Welte T, Wunderink RG: Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19. 10.1186/s13054-016-1197-5 - DOI - PMC - PubMed
1. Watkins RR, Deresinski S: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15(10):893–5. 10.1080/14787210.2017.1380519 - DOI - PubMed
1. Grundmann H, Glasner C, Albiger B, et al. : Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–63. 10.1016/S1473-3099(16)30257-2 - DOI - PubMed
2. F1000 Recommendation

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Thorpe KE, Joski P, Johnston KJ: Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Aff (Millwood). 2018;37(4):662–9. 10.1377/hlthaff.2017.1153 - DOI - PubMed

F1000 Recommendation

[2] Thorpe KE, Joski P, Johnston KJ: Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Aff (Millwood). 2018;37(4):662–9. 10.1377/hlthaff.2017.1153 - DOI - PubMed

[3] F1000 Recommendation

[4] Kalil AC, Metersky ML, Klompas M, et al. : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. 10.1093/cid/ciw353 - DOI - PMC - PubMed

F1000 Recommendation

[5] Kalil AC, Metersky ML, Klompas M, et al. : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. 10.1093/cid/ciw353 - DOI - PMC - PubMed

[6] F1000 Recommendation

[7] Bassetti M, Welte T, Wunderink RG: Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19. 10.1186/s13054-016-1197-5 - DOI - PMC - PubMed

[8] Bassetti M, Welte T, Wunderink RG: Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19. 10.1186/s13054-016-1197-5 - DOI - PMC - PubMed

[9] Watkins RR, Deresinski S: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15(10):893–5. 10.1080/14787210.2017.1380519 - DOI - PubMed

[10] Watkins RR, Deresinski S: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15(10):893–5. 10.1080/14787210.2017.1380519 - DOI - PubMed

[11] Grundmann H, Glasner C, Albiger B, et al. : Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–63. 10.1016/S1473-3099(16)30257-2 - DOI - PubMed

F1000 Recommendation

[12] Grundmann H, Glasner C, Albiger B, et al. : Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–63. 10.1016/S1473-3099(16)30257-2 - DOI - PubMed

[13] F1000 Recommendation

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Affiliations

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources